Novartis, a leading pharmaceutical company, continues to exhibit strong performance with rising relative strength in the stock market. Pertaining to value investing, industry experts are considering it a great dividend stock at present, remarking on its impressive first-quarter sales figures and an upgraded full-year guidance. The company recently acquired
Regulus Therapeutics, investing $1.7 billion, which escalated Novartis shares significantly. Furthermore, investment analyses indicate that the Novartis stock is undervalued at present, making it a potentially profitable investment.
Swiss Drugmaker has assured a boost in U.S. manufacturing, further positing it among the best foreign dividend stocks for investment. Another notable development has been their Q4 earnings consensus beating as drug sales surged.
Regulus CVR, following the acquisition deal, could be worth up to $3-$4 per share, according to analysts. Nevertheless, UBS has withdrawn its buy rating for Novartis and the stock has experienced a slight dip recently.
Novartis Stocks News Analytics from Thu, 18 Jul 2024 07:00:00 GMT to Tue, 20 May 2025 07:00:00 GMT -
Rating 7
- Innovation -1
- Information 9
- Rumor -2
